ARTICLE | Product Development
New binding domains, target combinations and molecule structures define the VEGF multispecifics to be presented at AACR 2025
By Lauren Martz, Executive Director, Biopharma Intelligence
April 8, 2025 9:34 PM UTC
As the industry awaits results from the global Phase III study of ivonescimab, Chinese biotechs have been expanding on the VEGF bispecific concept, exploring alternative designs that could further boost efficacy in solid tumors. At AACR 2025, at least 13 companies are presenting bispecific constructs that move beyond me-too therapies, aiming for greater differentiation.
Abstracts released ahead of the 2025 American Association for Cancer Research (AACR) meeting describe a new wave of VEGF bispecifics featuring alternative VEGF receptor binding domains, novel second targets, and trispecific formats that test whether three targets outperform two…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/655518/vegf-multispecifics-get-innovative-at-aacr-2025
